diranersen

News

Biogen and Ionis have revealed the first clinical results with tau-targeting Alzheimer's drug candidate diranersen, to a mixed response.

News

Biogen will advance its tau-targeting Alzheimer's disease drug diranersen into phase 3, even though it missed the main endpoint in a midstage trial.

Digital

In a new episode of the pharmaphorum podcast, Nicole Raleigh invites Mati Gill, CEO of AION Labs, back as guest.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.